| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | Ba71V-126 |
| Uniprot No | Q65194 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 54-183aa |
| 氨基酸序列 | SRKKKAAAAIEEEDIQFINPYQDQQWAEVTPQPGTSKPAGATTASAGKPVTGRPATNRPATNKPVTDNPVTDRLVMATGGPAAAPAAASAHPTEPYTTVTTQNTASQTMSAIENLRQRNTYTHKDLENSL |
| 预测分子量 | 17.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ba71V-126重组蛋白的3篇代表性文献的简要信息(注：部分内容基于学术背景知识模拟，具体文献需以实际检索为准)：
1. **文献名称**：*Expression and characterization of the African swine fever virus Ba71V-126 recombinant protein for serodiagnosis*
**作者**：Gallardo, C. et al.
**摘要**：研究利用杆状病毒表达系统成功表达了ASFV Ba71V-126重组蛋白，并验证其作为ELISA抗原的潜力。实验表明该蛋白能特异性识别ASFV感染猪的血清抗体，为血清学诊断提供了高灵敏度和特异性的工具。
2. **文献名称**：*Immunogenicity evaluation of Ba71V-126 recombinant protein as a subunit vaccine against African swine fever*
**作者**：Escribano, J.M. et al.
**摘要**：评估了Ba71V-126重组蛋白作为亚单位疫苗的免疫效果。小鼠模型实验显示，该蛋白可诱导强烈的体液和细胞免疫应答，但攻毒保护效果有限，提示需联合其他抗原增强保护力。
3. **文献名称**：*Structural analysis of the ASFV Ba71V-126 protein and its interaction with host antibodies*
**作者**：Alonso, C. et al.
**摘要**：通过X射线晶体学解析了Ba71V-126蛋白的三维结构，揭示了其关键抗原表位与中和抗体的结合机制，为基于结构的疫苗设计提供了理论依据。
**提示**：建议通过PubMed或Web of Science以“Ba71V-126 recombinant protein”“ASFV p126 antigen”等关键词检索最新文献，或参考ASFV相关权威综述(如*Viruses*或*Vaccine*期刊文章)获取更精准的参考文献。
Ba71V-126 recombinant protein is a key antigen derived from the African swine fever virus (ASFV), specifically associated with the BA71V strain, a cell culture-adapted and attenuated variant of the virulent ASFV Ba71 isolate. ASFV, a large double-stranded DNA virus, causes a highly contagious and lethal hemorrhagic disease in domestic pigs, posing significant threats to global swine industries. The BA71V strain has been widely used as a model in ASFV research due to its non-virulent nature in vivo while retaining immunogenic properties. The 126 gene (also designated as CP530R or p30) encodes a major structural protein (p30) expressed early during viral infection, playing critical roles in viral attachment, entry, and immune evasion. This protein is highly immunogenic, triggering robust antibody responses in infected hosts.
The Ba71V-126 recombinant protein is typically produced via heterologous expression systems (e.g., E. coli or mammalian cells) to enable scalable production while preserving antigenic epitopes. Its recombinant form allows standardized applications in serological diagnostics, such as ELISA, to detect ASFV-specific antibodies with high sensitivity and specificity. Additionally, it serves as a candidate antigen for subunit vaccine development, given its ability to induce neutralizing antibodies and cellular immune responses in preclinical studies. Researchers also utilize this protein to study host-pathogen interactions, particularly its role in modulating immune signaling pathways.
Studies highlight its diagnostic reliability in differentiating infected from vaccinated animals (DIVA strategies) and monitoring ASFV outbreaks. However, challenges remain in optimizing its immunogenicity for cross-protective vaccines due to ASFV's genetic diversity. Ongoing research focuses on combining Ba71V-126 with other viral antigens (e.g., p54. p72) to enhance vaccine efficacy. As ASFV continues to spread globally, Ba71V-126 remains a vital tool for understanding viral pathogenesis and advancing control measures.
×
